Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00094822 |
Recruitment Status
:
Completed
First Posted
: October 27, 2004
Last Update Posted
: February 13, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Lung Cancer Non-Small Cell Lung Cancer | Other: PI Discretion |
Study Type : | Observational |
Actual Enrollment : | 90 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer |
Study Start Date : | July 2003 |
Actual Primary Completion Date : | December 2005 |
Actual Study Completion Date : | February 2006 |

Group/Cohort | Intervention/treatment |
---|---|
Pegfilgrastim |
Other: PI Discretion
PI Discretion
|
PLACEBO |
Other: PI Discretion
PI Discretion
|
- incidence of infection [ Time Frame: during treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00094822
Study Director: | MD | Amgen |
Additional Information:
Responsible Party: | Global Development Leader, Amgen Inc. |
ClinicalTrials.gov Identifier: | NCT00094822 History of Changes |
Other Study ID Numbers: |
20030123 |
First Posted: | October 27, 2004 Key Record Dates |
Last Update Posted: | February 13, 2009 |
Last Verified: | February 2009 |
Keywords provided by Amgen:
Metastatic Cancer Neulasta® pegfilgrastim |
Additional relevant MeSH terms:
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic |
Bronchial Neoplasms Docetaxel Carboplatin Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |